HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT)
using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors
and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF)
for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
Center for International Blood and Marrow Transplant Research
Collaborators:
National Marrow Donor Program Resource for Clinical Investigation in Blood and Marrow Transplantation